An Adaptive Feeding and Cell Sorting Method for Bio-Magnetic Nanobeads Based on Flow Cytometry Pre-detection

By using flow cytometry to pre-examine and determine the cell load and adjust the amount of magnetic beads, the problem of inaccurate addition in magnetic sorting was solved, resulting in a more stable cell sorting effect.

CN123111925APending Publication Date: 2026-11-17GANSU RUIDE BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611394774.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-09
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

In existing technologies, the amount of magnetic sorting particles added during the magnetic sorting process is usually determined based on the sample volume or the total number of cells, which cannot accurately reflect the actual cell load to be bound, resulting in a decrease in the target cell recovery rate or non-specific binding, affecting the consistency of the sorting effect.

Method used

The actual cell load to be bound was determined by flow cytometry pre-screening, and the correspondence between the first type of cell load and the amount of bio-nanomagnetic beads used was established. The amount of magnetic beads added was adjusted to meet the needs of samples with different cell compositions. After the bio-nanomagnetic beads were bound to the cells, a magnetic field was applied for separation.

Benefits of technology

It improves the stability of the magnetic sorting process, reduces reagent consumption and non-specific binding, enhances the recovery and removal rates of target cells, and reduces batch-to-batch fluctuations in sorting performance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

This invention belongs to the field of cell sorting technology and discloses an adaptive feeding and cell sorting method based on flow cytometry pre-detection of bio-magnetic nanobeads. The method includes: mixing an ex vivo cell sample and obtaining pre-detection aliquots; detecting the proportion, concentration, absolute number, or cell load parameters of the first type of cells to be bound to the bio-magnetic nanobeads using flow cytometry, and determining the expected load of the first type of cells in the remaining samples to be sorted; determining the amount of bio-magnetic nanobeads to be added based on a pre-established correspondence between the first type of cell load and the amount of bio-magnetic nanobeads; binding the bio-magnetic nanobeads to the first type of cells according to the added amount, and separating the first type of cells from the second type of cells using a magnetic field. This invention enables the amount of bio-magnetic nanobeads to be used to match the actual cell load to be bound, reducing excessive particles in low-load samples and insufficient particles in high-load samples, and improving the consistency of sorting results between samples with different cell compositions.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of cell sorting technology, specifically relating to an adaptive feeding and cell sorting method for bio-nanomagnetic beads based on flow cytometry pre-detection. Background Technology

[0002] Flow cytometry can identify different cell populations using scattered light and fluorescence signals, and can obtain the proportion, absolute number, viability, and biomarker expression of specific cell populations. Therefore, flow cytometry is commonly used for cell composition detection before and after immunomagnetic sorting, as well as for evaluating sorting effectiveness.

[0003] In existing immunomagnetic sorting processes, the amount of magnetic sorting particles added is usually determined based on the sample volume, the total number of cells in the sample, or a pre-defined fixed feed ratio. However, even if different ex vivo cell samples have essentially the same sample volume or total number of cells, the actual number of cells that need to bind with the magnetic sorting particles may vary significantly.

[0004] When there are insufficient magnetic particles, some cells to be bound cannot be adequately magnetically labeled, which may lead to a decrease in the recovery rate of target cells during positive selection or insufficient removal of interfering cells during negative removal. Excessive magnetic particles not only increase the consumption of sorting reagents but may also increase non-specific cell adsorption, particle aggregation, particle residue, and loss of non-target cells, potentially affecting subsequent flow cytometry analysis. When the proportion of cells to be bound varies significantly between different batches of samples, even if the type of magnetic particles, incubation time, magnetic field conditions, and operators remain basically consistent, using a fixed dosage for magnetic sorting may still cause significant batch-to-batch fluctuations.

[0005] While existing technologies can detect sample composition using flow cytometry before magnetic sorting, pre-sorting flow cytometry is typically used for sample quality evaluation or process recording, and does not further convert the specific cell load to be combined with the magnetically sorted particles into the actual amount of magnetically sorted particles fed into the sample.

[0006] Therefore, there is a need for a method that can determine the amount of magnetic sorting particles based on the actual cell load in the sample, so as to avoid significant overfeeding for low-load samples and obtain sufficient magnetic particles for high-load samples, thereby improving the stability of the magnetic sorting process between samples with different cell compositions. Summary of the Invention

[0007] The purpose of this invention is to provide an adaptive feeding and cell sorting method for magnetic sorting particles based on flow cytometry pre-detection, in order to solve the problem that when magnetic sorting particles are added at a fixed amount according to the sample volume or total number of cells, the amount of magnetic sorting particles cannot accurately reflect the actual cell load to be bound.

[0008] To achieve the above objectives, the present invention adopts the following technical solution: On one hand, this invention provides an adaptive feeding and cell sorting method for bio-magnetic nanobeads based on flow cytometry pre-detection, comprising: The ex vivo cell samples containing the first type of cells and the second type of cells were mixed. Pre-detection equal-segmented samples were obtained from the mixed ex vivo cell samples, and the remaining samples were used as samples to be sorted. Flow cytometry is used to detect the pre-sorted samples. Based on at least one cell marker that can characterize the first type of cells, the proportion, concentration, absolute number of the first type of cells or detection parameters related to the first type of cell load are obtained, and the expected first type of cell load in the sample to be sorted is determined accordingly. Based on the expected load of the first type of cells and the pre-established correspondence between the load of the first type of cells and the amount of bio-nanomagnetic beads used, the amount of bio-nanomagnetic beads to be added to the sample to be sorted is determined. Bio-magnetic nanobeads are added to the samples to be sorted according to the determined dosage, allowing the bio-magnetic nanobeads to bind to type I cells through biorecognition ligands on their surface; and A magnetic field is applied to the samples to be sorted after the addition of bio-magnetic nanobeads, causing the first type of cells that are bound to the bio-magnetic nanobeads and the second type of cells that are not bound to the corresponding bio-magnetic nanobeads to separate.

[0009] The first type of cell referred to in this invention refers to cells that need to be combined with bio-nanomagnetic beads during the magnetic sorting process.

[0010] In the positive selection implementation, the first type of cells are the target cells that need to be enriched from the ex vivo cell sample, and magnetic components containing the first type of cells are obtained after magnetic separation.

[0011] In the negative removal implementation, the first type of cells are interfering cells or miscellaneous cells that need to be removed from the ex vivo cell sample, and after magnetic separation, a non-magnetic component mainly containing cells that have not been bound to the corresponding bio-nanomagnetic beads is obtained.

[0012] The second type of cell referred to in this invention refers to cells that do not need to be bound to biological nanomagnetic beads during the corresponding magnetic sorting process.

[0013] Preferably, the ex vivo cell samples include cell suspensions obtained from peripheral blood after in vitro processing, peripheral blood mononuclear cells, bone marrow cell suspensions, umbilical cord blood cell suspensions, leukocyte apheresis products, cell suspensions obtained from in vitro tissue dissociation, cell cultures, cell expansion products, intermediates or final products of cell products, and artificially prepared mixed cell samples.

[0014] Preferably, before obtaining the pre-sorted samples, the isolated cell samples are mixed by gently blowing, flipping, or rotating at low speed to improve the representativeness of the pre-sorted samples to the remaining samples to be sorted.

[0015] Preferably, the pre-detection sample accounts for 0.1% to 10% of the total volume of the mixed ex vivo cell sample.

[0016] More preferably, the pre-detection equal-divided samples account for 1% to 3% of the total sample volume.

[0017] Preferably, at least 5,000 valid cell events are collected when performing flow cytometry on the pre-detection aliquots.

[0018] When the proportion of the first type of cells in the sample is low, it is preferable that the number of first type of cell events detected is not less than 50, and more preferably not less than 100.

[0019] When the number of events in the first type of cells is lower than the preset minimum number of events, the sampling volume of the pre-detection aliquots can be increased, the number of events in the flow cytometry acquisition can be increased, the pre-detection aliquots can be re-acquired for detection, or the preset minimum operating dose of biological nanomagnetic beads can be used.

[0020] In a preferred embodiment, flow cytometry is used to determine the absolute concentration of the first type of cells using microspheres.

[0021] Specifically, a known number or concentration of flow cytometry microspheres is added to the pre-test aliquots. The number of events of the first type of cells and the number of events of the flow cytometry microspheres are obtained by flow cytometry, and the absolute concentration of the first type of cells is determined based on the relationship between the two.

[0022] The concentration of the first type of cells can be determined according to the following formula: C1=(E1 / E r )×(N r / V a ); in: C1 represents the concentration of first-order cells; E1 represents the number of first-order cell events detected by flow cytometry; E r N represents the number of events in the microspheres obtained by flow cytometry analysis. r The number of flow cytometry microspheres added to the pre-detection aliquots; V a This refers to the original sample volume used during pre-inspection sampling.

[0023] After obtaining the concentration of the first type of cells, the estimated number of the first type of cells in the sample to be sorted can be determined by the following formula: N1 = C1 × V s ; Where: N1 is the expected number of first-type cells in the sample to be sorted; C1 is the concentration of first-type cells; V s The volume of the sample to be sorted.

[0024] In another implementation, instead of using flow cytometry microspheres, the proportion P1 of the first type of cells to the predetermined cell population can be obtained by flow cytometry, and combined with the total number N of the predetermined cell population in the sample to be sorted. t Determine the expected number N1 of the first type of cells, where: N1 = N t ×P1.

[0025] The total number of cells in a predetermined cell population in a sample to be sorted can be obtained by flow cytometry, automated cell counter, hemocytometer or other methods suitable for cell counting.

[0026] This invention does not simply add bio-nanomagnetic beads in any proportion based on the number of the first type of cells. Instead, it preferably establishes a pre-established correspondence between the first type of cell load and the corresponding amount of bio-nanomagnetic beads, so that the amount of magnetic beads added is adapted to the specific bio-nanomagnetic beads, cell type, and magnetic sorting conditions.

[0027] Preferably, the relationship between the first type of cell load and the amount of bio-magnetic nanobeads used is established in the following way: Prepare or select a calibration sample containing a known number or proportion of type I cells; Different doses of the same type of bio-magnetic nanobeads were added to different calibration samples or different aliquots of the same calibration sample. The same or essentially the same incubation time, incubation temperature, mixing method, and magnetic separation conditions were used for treatment; The recovery or removal rate of type I cells was detected under different doses of biological magnetic nanobeads. Simultaneously detect the recovery rate and / or cell viability of the second type of cells as needed; and The reference dosage of bio-nanomagnetic beads corresponding to the first type of cell load is determined based on the preset sorting effect.

[0028] Preferably, the reference dosage is the lower dosage of bio-nanomagnetic beads that meets the preset sorting effect conditions.

[0029] For negative cell removal, one or more of the following can be used as evaluation indicators to determine the amount of magnetic beads used: removal rate of first-type cells, recovery rate of second-type cells, and cell viability.

[0030] Preferably, the removal rate of the first type of cells is not less than 80%; the recovery rate of the second type of cells is not less than 80%; and the cell viability is not less than 85%.

[0031] For positive selection, one or more of the following can be used as evaluation indicators to determine the amount of magnetic beads used: recovery rate of the first type of cells, purity of the first type of cells after sorting, and cell viability.

[0032] Preferably, the recovery rate of the first type of cells is not less than 60%; the purity of the first type of cells after sorting is not less than 70%; and the cell viability is not less than 85%.

[0033] The sorting effect thresholds mentioned above are mainly used to establish the dosage correspondence applicable to specific cell types, specific biological nanomagnetic beads, and specific sorting conditions, and do not require different applications to use the exact same evaluation thresholds.

[0034] In one implementation, the amount of bio-nanomagnetic beads used is calculated continuously based on the expected number of the first type of cells.

[0035] Preferably, the amount of bio-nanomagnetic beads used is determined according to the following formula: D = K × N1 × F; Where: D is the amount of bio-nanomagnetic beads to be added to the sample to be sorted; K is the bio-nanomagnetic bead usage coefficient corresponding to a unit number of first-type cells; N1 is the expected number of first-type cells in the sample to be sorted; and F is the safety factor.

[0036] Preferably, the safety factor F is 1.05 to 1.50.

[0037] Setting a safety factor can be used to compensate for potential biases in pre-screening, flow cytometry, and type I cell load estimation.

[0038] Preferably, a minimum operable dose D of the bio-magnetic nanobeads is further set. min When the magnetic bead dose calculated according to the first type of cell load is lower than D min When actually using D min .

[0039] Preferably, the maximum allowable dose D of bio-nanomagnetic beads in a single sorting can also be set. max When the calculated dose of bio-nanomagnetic beads exceeds D max When sorting samples, they can be divided into two or more sorting units for separate processing, or biological nanomagnetic beads can be added in batches for processing.

[0040] In another implementation, a segmented dosage table can be established based on the first type of cell load. Two, three, four, or more load intervals can be set according to the expected number of first type of cells, so that different first type of cell load intervals correspond to different dosages of bio-nanomagnetic beads.

[0041] When the expected load of the first type of cells falls into the corresponding load range, the predetermined dose of biological nanomagnetic beads corresponding to that load range is used.

[0042] Segmented dosimeters can be determined based on continuous dosing relationships, pre-calibration results, and actual pipetting accuracy, and can be used in standard operating procedures, experimental operation cards, or production process documents.

[0043] Preferably, the first type of cell marker used for flow cytometry pre-detection is the same as the cell marker recognized by the biorecognition ligand on the surface of the bio-nanomagnetic beads.

[0044] In another implementation, the cell markers used for flow cytometry pre-screening are different from those recognized by the bio-nanomagnetic beads, but both are stably co-expressed on the first type of cells.

[0045] When using different cell markers for pre-detection and magnetic capture, it is preferable to confirm in advance through a control experiment that the positive cell load of the pre-detection marker and the positive cell load of the magnetic bead capture marker are consistent enough to meet the requirements of magnetic bead dosing accuracy.

[0046] Preferably, the bio-magnetic nanobeads include magnetic nanoparticles with magnetic responsiveness and bio-recognition ligands disposed on the surface of the magnetic nanoparticles.

[0047] Biorecognition ligands are selected from one or more of antibodies, antibody fragments, aptamers, lectins, receptors, ligand proteins, and polypeptides.

[0048] Preferably, the magnetic nanoparticles exhibit superparamagnetism.

[0049] Preferably, the nominal average particle size of the magnetic nanoparticles is 20–500 nm.

[0050] More preferably, the nominal average particle size is 50–300 nm.

[0051] After the bio-magnetic nanobeads come into contact with the sample to be sorted, they recognize and bind to the first type of cells through the bio-recognition ligands on their surface.

[0052] Preferably, the incubation time between the bio-magnetic nanobeads and the sample to be sorted is 5 to 45 minutes.

[0053] More preferably, the time is 10 to 30 minutes.

[0054] Preferably, the incubation temperature is 2–37°C.

[0055] More preferably, the temperature is selected as 2–8℃ or 18–25℃ depending on the cell type and the type of bio-nanomagnetic beads.

[0056] During incubation, gentle turning, low-speed rotation, or intermittent blowing can be used to promote full contact between the bio-nanomagnetic beads and the first type of cells.

[0057] After incubation, a magnetic field is applied to the sample.

[0058] Preferably, the sample is placed in a magnetic field for 1 to 15 minutes.

[0059] When the first type of cells are interfering cells that need to be removed from the ex vivo cell sample, the bio-magnetic nanobeads combine with the first type of cells to form a magnetic component, and collect the non-magnetic components that are not retained by the magnetic field as the target cell component.

[0060] When the first type of cells are the target cells that need to be enriched from the ex vivo cell sample, the bio-magnetic nanobeads combine with the first type of cells to form a magnetic component, and the magnetic component is collected as the target cell component.

[0061] After magnetic separation is completed, the obtained magnetic and / or non-magnetic components can be analyzed by flow cytometry as needed to obtain one or more of the following: number, proportion, purity, recovery rate, removal rate, and viability of type I or type II cells.

[0062] Post-sorting testing is mainly used to evaluate the magnetic sorting effect, establish or correct the correspondence between the amount of bio-nanomagnetic beads used, and to carry out process quality control. It is not a necessary step for implementing the adaptive magnetic sorting method of this invention.

[0063] Compared with the prior art, the present invention has the following beneficial effects: 1. This invention first uses flow cytometry to determine the actual type I cell load that needs to bind to the bio-magnetic nanobeads, and then determines the amount of magnetic beads to be added accordingly. This transforms the basis for bio-magnetic nanobead dosing from sample volume or total cell count to the actual cell load to be bound. For samples with a low proportion of type I cells, unnecessary bio-magnetic nanobead addition can be reduced, thereby reducing reagent consumption and minimizing non-specific binding, cell loss, and magnetic bead residue that may result from excessive magnetic beads. For samples with a high proportion of type I cells, the amount of bio-magnetic nanobeads can be increased according to the actual type I cell load, thereby reducing incomplete magnetic labeling due to insufficient fixed dosage and improving the removal rate of interfering cells or the recovery rate of target cells.

[0064] 2. This invention establishes a pre-defined relationship between the first-type cell load and the amount of bio-nanomagnetic beads used, allowing the bead dosage to be tailored to the specific bio-nanomagnetic beads, cell type, and sorting conditions, rather than simply converting cell number into bead dosage in an arbitrary ratio. When different samples have similar total cell numbers but significantly different proportions of the first-type cells, this invention reduces the impact of variations in the first-type cell load on the sorting effect, thereby improving the consistency of sorting results between different samples.

[0065] 3. This invention does not require changing the basic material composition of existing bio-magnetic nanobeads, nor does it require redesigning magnetic sorting equipment. It can be implemented using existing flow cytometers, counting microspheres, magnetic racks, or other conventional magnetic sorting equipment, as well as commercially available bio-magnetic nanobeads. The correspondence between the first type of cell load and the amount of bio-magnetic nanobeads established in this invention can be further converted into continuous dose calculation rules or segmented dose tables, facilitating the formation of standardized cell sorting operation procedures. Detailed Implementation

[0066] To enable those skilled in the art to better understand the present application, the technical solutions in specific embodiments of the present application will be clearly and completely described below. Unless otherwise defined, the technical or scientific terms used in this invention should have the ordinary meaning understood by those skilled in the art.

[0067] The bio-magnetic nanobeads used in this example are superparamagnetic nanobeads with corresponding antibodies conjugated to their surfaces, with a nominal average particle size of approximately 100–250 nm. The sorting buffer is phosphate buffer containing 1.0% bovine serum albumin and 2 mmol / L EDTA. For flow cytometry detection, CD45, CD19, and CD3 fluorescent antibodies and live / dead dyes are selected according to the target cell, and absolute counting is performed using flow cytometry microspheres. Flow cytometry analysis sequentially sets cell gates, single-cell gates, live-cell gates, and corresponding cell phenotype gates, collecting no fewer than 20,000 valid cellular events for each pre-test sample.

[0068] Example 1 First, the correlation between CD19-positive cell load and the amount of anti-CD19 bio-magnetic nanobeads was established. Multiple batches were prepared with a total cell count of approximately 1×10⁻⁶. 7 The number of CD19-positive cells was approximately 1 × 10⁻⁶. 6 One peripheral blood mononuclear cell calibration sample was collected. The calibration samples were grouped, with each group consisting of 1 × 10⁻⁶ cells. 6CD19-positive cells were added to 6 μL, 9 μL, 12 μL, 18 μL, and 24 μL of anti-CD19 bio-magnetic nanobeads, with three replicates for each group. After adding the magnetic beads, the cells were incubated at low speed at 20–25 °C for 20 minutes, then placed in a magnetic rack for 5 minutes to collect the non-magnetic fraction. The magnetic fraction was washed once with 1 mL of sorting buffer, and the resulting non-magnetic fractions were combined. The removal rate of CD19-positive cells, the recovery rate of CD3-positive cells, and the viable cell rate were detected by flow cytometry. The results are shown in Table 1.

[0069] Table 1: Sorting results of different unit dosages of anti-CD19 bio-nanomagnetic beads

[0070] The results showed that the removal rate of CD19-positive cells increased with the increase of the amount of magnetic beads corresponding to each CD19-positive cell; however, the recovery rate of unbound CD3-positive cells decreased with further increases in the amount of magnetic beads. A preset sorting effect was defined as a CD19-positive cell removal rate of not less than 90% and a CD3-positive cell recovery rate of not less than 88%, using 12 μL / 1×10⁻⁶ beads. 6 One CD19-positive cell is sufficient to meet the aforementioned conditions. Therefore, in this embodiment, the magnetic bead dosage coefficient K corresponding to one unit of CD19-positive cells is determined as follows: K = 12 μL / 1 × 10 6 CD19-positive cells were used. A safety factor of 1.20 was employed. Peripheral blood mononuclear cell samples with low, medium, and high CD19-positive cell loads were then prepared. The total volume of each sample was 1 mL, and the total cell count was approximately 1 × 10⁻⁶ cells. 7 The samples were divided into three groups, with CD19 positive cells accounting for approximately 2%, 10%, and 30%, respectively. After each sample was gently mixed, 50 μL was taken as a pre-screening aliquot, and the remaining 950 μL was taken as the sample to be sorted.

[0071] The absolute concentration of CD19-positive live cells in the pre-sorted samples was determined by flow cytometry and counting microspheres, and the expected number of CD19-positive cells in the samples to be sorted was calculated accordingly.

[0072] The estimated number of CD19-positive cells in low, medium, and high load samples was approximately 0.20 × 10⁻⁶. 6 0.97×10 6 The sum is 2.83 × 10 6 indivual.

[0073] The dosage of bio-nanomagnetic beads was calculated according to the formula: D = K × N1 × F, where K is 12 μL / 1 × 10 6 CD19 positive cells, F = 1.20.

[0074] The minimum operating dose was set to 5 μL, so 5 μL, 14 μL and 41 μL of anti-CD19 biomagnetic nanobeads were actually added to the low, medium and high load samples, respectively.

[0075] After adding the magnetic beads, incubate at low speed for 20 minutes at 20-25°C, place in a magnetic rack for 5 minutes, collect the non-magnetic components, and perform a magnetic wash.

[0076] Example 2 In this embodiment, anti-CD3 bio-magnetic nanobeads were used for positive selection of CD3-positive cells. Following the same pre-calibration principle as in Example 1, the recovery rate of CD3-positive cells, the purity of enriched CD3-positive cells, and cell viability were detected at different doses of anti-CD3 bio-magnetic nanobeads.

[0077] Based on the pre-calibration results, the unit dosage coefficient K of the anti-CD3 bio-magnetic nanobeads was determined as: K = 15 μL / 1 × 10⁻⁶ 6 500 CD3-positive cells. The safety factor F was set at 1.15, and the minimum operating dose was 5 μL. The total number of cells prepared was approximately 5 × 10⁻⁶. 6 Three CD3-positive cell load samples were collected, with low, medium, and high CD3-positive cell proportions of approximately 5%, 20%, and 50%, respectively.

[0078] Five percent of the total volume of each sample was used as a pre-test sample, and the absolute concentration of CD3 positive cells was determined by flow cytometry and counting microspheres.

[0079] Calculations show that the estimated number of CD3-positive cells in the remaining samples to be sorted is approximately 0.24 × 10⁻⁶. 6 0.95×10 6 The sum is 2.38 × 10 6 Based on the aforementioned K value and safety factor, 5 μL, 17 μL, and 41 μL of anti-CD3 bio-magnetic nanobeads were used for low, medium, and high load samples, respectively.

[0080] After adding the magnetic beads, the sample was incubated at low speed for 20 minutes at 20-25°C. The sample was then placed in a magnetic rack for 5 minutes to remove the non-magnetic supernatant. The magnetic components were washed once and then resuspended to obtain the CD3-positive cell enrichment component.

[0081] Comparative Example 1 In this comparative example, anti-CD19 bio-magnetic nanobeads were added at a fixed total cell count. The same low, medium, and high CD19 load samples as in Example 1 were used. No adjustments were made to the amount of magnetic beads based on the CD19-positive cell load; instead, the total cell count of each sample was kept constant. The total cell count of each sample was approximately 1 × 10⁻⁶. 6Therefore, 20 μL of anti-CD19 bio-magnetic nanobeads were added to all samples, including low, medium, and high load samples. The remaining incubation, magnetic separation, and detection conditions were the same as in Example 1.

[0082] Comparative Example 2 This comparative example measures CD19 positive cell load without establishing a pre-calibration relationship for magnetic bead dosage. It uses the same low, medium, and high CD19 load samples as in Example 1, and determines the expected number of CD19 positive cells in each sample to be sorted by flow cytometry.

[0083] This comparative example does not establish a magnetic bead dosage coefficient based on CD19 removal rate and CD3 recovery rate at different unit magnetic bead dosages, but directly uses a preset 8μL / 1×10 6 Using CD19-positive cells as the conversion ratio, without setting a safety factor, the minimum operating dose remains 5 μL.

[0084] Therefore, 5 μL, 8 μL, and 23 μL of anti-CD19 bio-magnetic nanobeads were added to low, medium, and high load samples, respectively. All other conditions were the same as in Example 1.

[0085] Comparative Example 3 This comparative example used the same low, medium, and high CD3-positive cell load samples as in Example 2. Each sample was consistently supplemented with 20 μL of anti-CD3 bio-magnetic nanobeads, without adjusting the amount of magnetic beads based on the expected number of CD3-positive cells in the sample to be sorted. The remaining incubation, magnetic separation, and detection conditions were the same as in Example 2.

[0086] Test case The test items and methods used in this test case are as follows: For CD19-negative removal, the CD19-positive cell removal rate is calculated using the following formula: CD19 positive cell removal rate = (Expected number of CD19 positive cells before sorting - Number of CD19 positive cells after sorting) ÷ Expected number of CD19 positive cells before sorting × 100%.

[0087] CD3-positive cell recovery rate was calculated using the following formula: CD3 positive cell recovery rate = number of CD3 positive cells after sorting ÷ expected number of CD3 positive cells in the sample to be sorted before sorting × 100%.

[0088] For CD3-positive selection, the CD3-positive cell recovery rate is calculated using the following formula: CD3-positive cell recovery rate = (Number of CD3-positive cells in magnetic fraction ÷ Expected number of CD3-positive cells before sorting) × 100%.

[0089] CD3-positive cell purity is the proportion of CD3-positive live cells to the total number of live cells in the magnetic component.

[0090] The detection results of Example 1, Comparative Example 1, and Comparative Example 2 are shown in Table 2.

[0091] Table 2: Summary of sorting results for different feeding methods under different CD19 loads

[0092] The results showed that for low-load samples, Comparative Example 1, with a fixed addition of 20 μL of magnetic beads, achieved a higher CD19 removal rate, but the amount of magnetic beads used was four times that of Example 1, and the CD3-positive cell recovery rate was lower than that of Example 1. Example 1, using only 5 μL of anti-CD19 bio-magnetic nanobeads, maintained a CD19 removal rate of over 90%.

[0093] For medium-load samples, Example 1 used 14 μL of magnetic beads to achieve a CD19 removal effect that is basically equivalent to that of fixed 20 μL, while maintaining a slightly higher CD3 positive cell recovery rate.

[0094] For high-load samples, when Comparative Example 1 still used 20 μL of magnetic beads, the CD19 removal rate decreased to 79.6%; in Example 1, after increasing the magnetic bead dose to 41 μL based on the actual CD19 positive cell load obtained from the pre-detection, the CD19 removal rate reached 91.3%.

[0095] Therefore, when the total number of cells is basically the same but the CD19 positive cell load changes significantly from low to high, a fixed magnetic bead dosage cannot be applied to samples with different loads at the same time; adaptively adjusting the magnetic bead dosage according to the first type of cell load can reduce the fluctuation of sorting effect between samples with different loads.

[0096] Although the number of CD19 positive cells in Comparative Example 2 was obtained by flow cytometry, the amount of magnetic beads added to the medium and high load samples was still insufficient because an effective relationship between the amount of magnetic beads and the sorting conditions was not established in advance. The CD19 removal rates were only 86.3% and 82.7%, respectively.

[0097] The results indicate that the technical effect of the present invention is not only derived from the determination of the number of first-type cells before sorting, but also from the establishment of a correspondence between the first-type cell load and the amount of bio-nanomagnetic beads used in advance based on the actual sorting effect.

[0098] The results of Example 2 and Comparative Example 3 are shown in Table 3.

[0099] Table 3: Positive selection results under different CD3-positive cell loads

[0100] The results showed that in low-load CD3-positive cell samples, when the amount of anti-CD3 bio-magnetic nanobeads was reduced from a fixed dose of 20 μL to 5 μL, the recovery rate and purity of CD3-positive cells only changed slightly, indicating that there was a certain amount of magnetic beads excess at the fixed dose under low-load conditions.

[0101] For medium-load samples, the 17μL adaptive dose and the 20μL fixed dose achieved essentially the same sorting effect.

[0102] For high-load samples, the CD3-positive cell recovery rate dropped to 71.7% when fixed with 20 μL of magnetic beads. However, when the amount of magnetic beads was increased to 41 μL according to the expected CD3-positive cell load, the CD3-positive cell recovery rate increased to 82.4%, and the purity after sorting was also improved.

[0103] The above results indicate that determining the amount of bio-nanomagnetic beads based on the actual cell load to be bound obtained from flow cytometry pre-detection is applicable not only to negative sorting that requires the removal of type I cells, but also to positive sorting that requires the enrichment of type I cells.

[0104] In summary, when the total number of cells or the sample volume of an ex vivo cell sample cannot accurately reflect the number of cells to be bound to the bio-magnetic nanobeads, this invention uses flow cytometry to pre-obtain the first type of cell load and determines the amount of magnetic beads to be added based on the pre-established correspondence between the first type of cell load and the amount of bio-magnetic nanobeads. This allows low-load samples to reduce unnecessary magnetic bead usage and high-load samples to obtain a sufficient magnetic bead dose, thereby improving the consistency of magnetic sorting effects between samples with different cell loads.

[0105] Finally, it should be noted that the described embodiments are merely some, not all, of the embodiments of the present invention. Those skilled in the art will understand that various changes, modifications, substitutions, and variations can be made to these embodiments without departing from the principles and spirit of the present invention. The scope of the present invention is defined by the claims and their equivalents; that is, all other embodiments obtained by those skilled in the art based on the embodiments of the present invention without inventive effort are within the scope of protection of the present invention.

Claims

1. A method for adaptive feeding and cell sorting of bio-nanomagnetic beads based on flow cytometry pre-detection, characterized in that, Includes the following steps: The ex vivo cell samples containing the first type of cells and the second type of cells were mixed. Pre-detection equal-segmented samples were obtained from the mixed ex vivo cell samples, and the remaining samples were used as samples to be sorted. Flow cytometry was used to detect the pre-sorted samples. Based on at least one cell marker that can characterize the first type of cells, the proportion, concentration or absolute number of the first type of cells in the pre-sorted samples was obtained, and the expected load of the first type of cells in the samples to be sorted was determined accordingly. The first type of cells are the cells to be bound to the bio-magnetic nanobeads. Based on the expected load of the first type of cells and the pre-established correspondence between the load of the first type of cells and the amount of bio-nanomagnetic beads used, the amount of bio-nanomagnetic beads to be added to the sample to be sorted is determined. Add bio-magnetic nanobeads to the sample to be sorted according to the determined dosage, so that the bio-magnetic nanobeads bind to the first type of cells through bio-recognition ligands; and apply a magnetic field to the sample to be sorted after the addition of bio-magnetic nanobeads, so that the first type of cells bound to the bio-magnetic nanobeads and the second type of cells not bound to the bio-magnetic nanobeads are separated. The first type of cells are either target cells that need to be enriched from isolated cell samples, or interfering cells that need to be removed from isolated cell samples.

2. The method according to claim 1, characterized in that, Flow cytometry analysis of pre-screened aliquoted samples includes: Add a known number or a known concentration and volume of flow cytometry microspheres to the pre-test aliquots; The number of events in the first type of cells and the number of events in the microspheres were obtained by flow cytometry; and the absolute concentration of the first type of cells in the pre-screening aliquots was determined based on the number of events in the first type of cells and the number of events in the microspheres; the expected number of the first type of cells in the samples to be sorted was determined according to the following formula: N1=C1×V s ; Where N1 is the expected number of first-type cells in the sample to be sorted, C1 is the concentration of first-type cells obtained by flow cytometry, and V s The volume of the sample to be sorted.

3. The method according to claim 1, characterized in that, The proportion P1 of the first type of cells to the predetermined cell population was obtained by flow cytometry, and combined with the total number N of the predetermined cell population in the sample to be sorted. t Determine the expected number N1 of the first type of cells, where: N1=N t ×P1.

4. The method according to claim 1, characterized in that, The correlation between the first type of cell load and the amount of bio-magnetic nanobeads used was established in advance using the following method: Prepare or select a calibration sample containing a known number or proportion of first-type cells; add different doses of bio-magnetic nanobeads to different calibration samples or different aliquots of the same calibration sample; process under the same incubation and magnetic separation conditions; detect the recovery rate or removal rate of first-type cells at each dose of bio-magnetic nanobeads, and detect the recovery rate and / or cell viability of second-type cells; and determine the reference dosage of bio-magnetic nanobeads corresponding to the corresponding first-type cell load based on the preset sorting effect.

5. The method according to claim 1, characterized in that, The dosage of bio-nanomagnetic beads is determined according to the following formula: D = K × N1 × F; Where D is the amount of bio-nanomagnetic beads used, K is the bio-nanomagnetic bead usage coefficient corresponding to a unit number of first-type cells, N1 is the expected number of first-type cells in the sample to be sorted, and F is the safety factor; the safety factor F is 1.05 to 1.

50.

6. The method according to claim 5, characterized in that, When the calculated amount of bio-nanomagnetic beads is lower than the preset minimum operating dose, the minimum operating dose shall be used; when the calculated amount of bio-nanomagnetic beads is higher than the preset maximum single operating dose, the sample to be sorted shall be divided into at least two sorting units for magnetic sorting, or the bio-nanomagnetic beads shall be added in batches.

7. The method according to claim 1, characterized in that, The first type of cell load is divided into at least two load intervals, with each load interval corresponding to a predetermined amount of bio-nanomagnetic beads. The amount of bio-nanomagnetic beads added is determined based on the load interval to which the expected first type of cell load of the sample to be sorted belongs.

8. The method according to claim 1, characterized in that, The pre-detection aliquots comprise 0.1% to 10% of the total volume of the mixed ex vivo cell sample; at least 5000 valid cell events are collected when performing flow cytometry on the pre-detection aliquots. The cell markers used to characterize the first type of cells are the same as the cell markers recognized by the biorecognition ligands on the bio-nanomagnetic beads, or the two are stably co-expressed on the first type of cells.

9. The method according to claim 1, characterized in that, Bio-magnetic nanobeads include magnetic nanoparticles and biorecognition ligands disposed on the surface of the magnetic nanoparticles; the biorecognition ligands are at least one of antibodies, antibody fragments, aptamers, lectins, receptors, ligand proteins, and peptides.

10. The method according to claim 9, characterized in that, When the first type of cells are interfering cells that need to be removed from the ex vivo cell sample, the non-magnetic components after magnetic separation are collected as the target cell components; when the first type of cells are target cells that need to be enriched from the ex vivo cell sample, the magnetic components after magnetic separation are collected as the target cell components.